In Re Vioxx Products Liability Litigation

448 F. Supp. 2d 737, 2006 WL 2504350
District Court, E.D. Louisiana·Decided August 30, 2006·No. MDL NO. 1657·Published·Cited by 2 cases

Opinion

*738 ORDER & REASONS

FALLON, District Judge.

Following the announcement of the jury verdict in this case, the Defendant made several oral motions. For the following reasons, IT IS ORDERED that there shall be a new trial on the issue of damages. Accordingly, the - Defendant’s post-trial oral motions are DENIED AS MOOT.

I. Background

This is a products liability case involving the prescription drug Vioxx, which was manufactured by Merck & Co., Inc. (“Merck”). The Plaintiff, Mr. Gerald Barnett, is a former FBI agent and a citizen of South Carolina. He was first prescribed Vioxx in 1999 to relieve his chronic neck and back pain. The Plaintiff alleges that Vioxx caused a heart attack he suffered in September of 2002 at the age of fifty-eight. The Plaintiff continued to take Vioxx until 2004, when it was withdrawn from the market.

On January 31, 2006, the Plaintiff brought suit against Merck in this Court and his case became part of MDL No. 1657. With the consent of both the Plaintiff and Merck, this case was set for trial. The Plaintiffs case was tried to a jury in New Orleans from July 31 until August 17, 2006.

The Plaintiff sought recovery under any of three theories of liability proscribed by South Carolina law: (1) Strict liability failure to warn-the Plaintiff alleged that Merck failed to adequately warn his treating physicians of a known or reasonably scientifically or medically knowable risk associated with Vioxx; (2) Negligent failure to warn-the Plaintiff alleged that Merck was negligent in failing to adequately warn his treating physicians of a known or reasonably scientifically or medically knowable risk associated with Vioxx; (3) Deceit by concealment-the Plaintiff alleged that Merck knowingly misrepresented or failed to disclose a material fact to his treating physicians in a circumstance where it was required to do so, that his treating physicians were entitled to and did rely on that misrepresentation or nondisclosure.

The jury returned a verdict in favor of the Plaintiff on two of his three theories of liability and awarded him $50 million in *739 compensatory damages. Specifically, the jury found that (1) Merck was negligent in failing to adequately warn the Plaintiffs treating physicians of a known or reason-ábly scientifically or medically knowable risk associated with Vioxx and that such negligence was a legal cause of the Plaintiffs injuries and (2) that Merck knowingly misrepresented or failed to disclose a material fact to the Plaintiffs treating physicians in a circumstance where it was required to do so, that the Plaintiffs treating physicians were entitled to and did rely on that misrepresentation or nondisclosure, and that the misrepresentation or nondisclosure was a legal cause of the Plaintiffs injuries. The jury found for Merck on the Plaintiffs strict liability claim, finding that Merck did not fail to adequately warn the Plaintiffs treating physicians of a known or reasonably scientifically or medically knowable risk associated with Vioxx.

Following the announcement of the verdict, the Defendant orally moved for judgment notwithstanding the verdict, or alternatively, for a new trial. Merck argues that the jury’s failure to warn findings are inconsistent. Specifically, Merck argues that the defense verdict on strict liability failure to warn should exonerate it on the negligent failure to warn claim, given that the later claim is identical to the former except for the added element of fault. The Court took this motion under submission.

The Court then informed the jury that having found for the Plaintiff, they would now consider the issue of punitive damages. Counsel presented additional evidence and argument on this issue and the jury retired to deliberate again. Shortly thereafter, the jury returned a verdict in favor of the Plaintiff on the issue of punitive damages, finding by clear and convincing evidence that Merck’s conduct was willful, wanton, or in reckless disregard of the Plaintiffs rights, and awarded the Plaintiff an additional $1 million.

Following the announcement of the punitive damages verdict, the Defendant orally moved for judgment as a matter of law, or in the alternative, for a mistrial on the punitive damages issue. Merck argues that Plaintiffs counsel improperly argued during the punitive damages phase of the trial that the jury should award punitive damages because otherwise Merck would continue to defend itself in courtrooms around the country. 1 Merck also argues that Plaintiffs counsel improperly referred to national sales figures during his argument. The Court took this motion under submission as well.

The verdicts were entered into the record, and the judgment has now been entered.

II. Law & Analysis

When considering a motion for judgment notwithstanding the verdict, the Court must consider all of the evidence in the light most favorable to the non-moving party. See Boeing v. Shipman, 411 F.2d 365, 374-75 (5th Cir.1969). The motion should be granted only when the facts and inferences point so strongly and overwhelmingly in favor of one party that the Court believes that a reasonable jury could not arrive at a contrary verdict. Id. It is the province of the jury, and not the Court, to weigh conflicting evidence and determine the credibility of witnesses. Id.

The Court takes this opportunity to note that the jury’s findings on liability are reasonable in this case. All three of the Plaintiffs claims revolve around the safety risks of Vioxx, what Merck knew about any such risks, when Merck knew this information, and what Merck should have *740 done about it. Considering all of the evidence in the light most favorable to the Plaintiff, the Court concludes that the jury’s findings for the Plaintiff on his negligent failure-to-warn and deceit-by-concealment claims were reasonable.

The Defendant argues, however, that the jury’s findings on strict liability failure to warn and negligent failure to warn are inconsistent, and therefore that it is entitled to judgment as a matter of law. The Court finds it unnecessary to address this issue. Assuming arguendo that these two findings are inconsistent, the inconsistency would, at most, require the Court to enter judgment for Merck on the negligent failure-to-warn claim. However, it is equally plausible that this inconsistency could require the Court to enter judgment for the Plaintiff on the strict liability failure to warn claim. Both results are logically defensible, depending upon which finding is used to initiate the chain of reasoning. 2 Regardless, the jury’s finding for the Plaintiff on the deceit by concealment claim would be unaffected by either potential consequence, and thus he would still be entitled to damages.

The Court “on its own, may order a new trial for any reason that would justify granting one on a party’s motion.” Fed.R.Civ.P.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Vioxx Products Liability Litigation, 448 F. Supp. 2d 737, 2006 WL 2504350 (E.D. La. 2006).

448 F. Supp. 2d 737 (In Re Vioxx Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In re Vioxx Products Liability Litigation
239 F.R.D. 450 (E.D. Louisiana, 2006)